Holen Sie sich die Stockscreener-App
12.10
5.22%
0.60
Handel nachbörslich:
12.26
0.16
+1.32%
Avantor Inc Aktie (AVTR) Neueste Nachrichten
Engine Capital to Push Avantor to Make Changes or Sell Itself - Eurasia Business News
Avantor shares jump as activist investor presses new CEO for cuts - Inquirer.com
Avantor Stock Jumps As Activist Investor Urges Sale, Board Shake-Up, And Cost Cuts - AOL.com
Why Avantor (AVTR) Stock Is Trading Up Today - TradingView
Cannabis stocks, Avantor, Albemarle: Trending Tickers - Yahoo Finance
Avantor Appoints Emmanuel Ligner as New CEO to Lead Next Phase of Growth - MSN
Activist Investor to Push Avantor to Make Changes or Sell Itself - The Wall Street Journal
Activist investor Engine Capital urges board overhaul at life sciences firm Avantor - Reuters
Avantor Responds To Activist Investor Engine Capital’s Letter: ‘Acting With Urgency To Strengthen Growth’ By Stocktwits - Investing.com India
Avantor rises after activist investor Engine Capital builds stake - TradingView
Activist Hammers Medtech For 'Self-Inflicted' Issues; Shares Spike - Investor's Business Daily
Avantor responds to activist investor, confirms new CEO next week By Investing.com - Investing.com Australia
Avantor reiterates shareholder value creation focus - MarketScreener
Activist investor Engine Capital urges Avantor to refresh board with new directors - 1470 & 100.3 WMBD
Avantor Accelerates $400M Transformation Plan as New CEO Takes Helm Amid Activist Pressure - Stock Titan
Avantor Stock Is Rising. An Activist Wants Changes, Maybe a Sale. - Barron's
Avantor Soars 10.43% on Acquisition Hopes - AInvest
Avantor rallies as Engine Capital calls for board change (AVTR:NYSE) - Seeking Alpha
Engine Capital urges Avantor to consider sale or strategic changes By Investing.com - Investing.com Canada
Activist Catalysts and Shareholder Value: Evaluating Engine Capital's Push for Avantor's Re-Rating - AInvest
Avantor rises after activist investor Engine Capital builds stake in co - TradingView
Engine Capital Demands Major Overhaul at Avantor: Claims Path to Double Share Price by 2027 - Stock Titan
Avantor Faces Activist Pressure: A Strategic Crossroads for the Lab Essentials Giant - AInvest
Avantor Under Pressure From Engine Capital to Explore Options - MarketScreener
Engine Capital builds 3% stake in Avantor to press for strategic changes, salereport - MSN
How Investors Are Reacting To Avantor (AVTR) Lowering Guidance After Weak Q2 Sales and Profits - simplywall.st
Engine Capital builds stake in Avantor, plans to push it to sell itself, WSJ reports - TradingView
Avantor Faces Pressure To Weigh A Potential Sale - Finimize
Activist investor Engine Capital to push Avantor to sell itself- WSJ By Investing.com - Investing.com Australia
Avantor's Strategic Crossroads: Activist Pressure, Liquidity, and Shareholder Value - AInvest
Exclusive | Activist Investor to Push Avantor to Make Changes or Sell Itself - The Wall Street Journal
Activist investor Engine Capital adds Avantor stake, pushes it to sell itself, WSJ reports - TradingView
Exclusive | Activist Investor to Push Avantor to Sell Itself - The Wall Street Journal
Avantor Inc. Flashes Buy Signal on Multi Timeframe ChartWeekly Stock Opportunity Radar Scanner Activated - metal.it
Avantor (NYSE:AVTR) Strong Profits May Be Masking Some Underlying Issues - 富途牛牛
Solid Earnings May Not Tell The Whole Story For Avantor (NYSE:AVTR) - uk.finance.yahoo.com
Avantor slips after adjusted profit miss - MSN
Avantor Posts Mixed Q2 Results Amid Leadership Transition and Segment Reshuffling - MSN
Avantor (AVTR) Is Down 15.3% After Lowering 2025 Revenue Outlook and Reporting Weaker Q2 Results – Has The Bull Case Changed? - simplywall.st
Avantor SVP Eck Steven W sells 3,476 shares at $11.39 per share on Aug 5. - AInvest
Avantor Second Quarter 2025 Earnings: EPS Misses Expectations - Yahoo Finance
Avantor Q2 Revenue Tops Estimates - AOL.com
Analysts' Bullish Sentiments on Healthcare Companies: Avantor, Nuvalent, and Alphatec Holdings - AInvest
Avantor Q2 Revenue Tops Estimates - The Motley Fool
JP Morgan Lowers Avantor Price Target to $14.00, Maintains "Overweight" Rating - AInvest
Avantor stock price target lowered to $17 at RBC Capital on revenue headwinds - Investing.com Australia
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN), Eli Lilly & Co (LLY) and Avantor (AVTR) - The Globe and Mail
AVTR Stock Declines as Q2 Earnings Miss Estimates, Revenues Down Y/Y - Yahoo Finance
Stifel lowers Avantor stock price target to $12 on bioprocess growth concerns - Investing.com India
Research Alert: CFRA Retains Hold Opinion On Shares Of Avantor, Inc. - 富途牛牛
UBS lowers Avantor stock price target to $13 on bioprocessing headwinds - Investing.com Australia
UBS lowers Avantor stock price target to $13 on bioprocessing headwinds By Investing.com - Investing.com South Africa
Avantor: Barclays Downgrades to Overweight with $13 Price Target from $15. - AInvest
Analysts' Opinions on Bausch + Lomb Corporation, Avantor, and AptarGroup: A Mixed Bag - AInvest
PE firm Audax buys Avantor’s clinical business for $650m - BioXconomy
Deutsche Bank Trims Avantor Price Target to $14 From $15, Maintains Hold Rating - MarketScreener
3.62%
0.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):